Skip to main content

Lineage Cell Therapeutics, Inc 10-Q for FY2026 Q3

Lineage Cell Therapeutics, Inc. (LCTX)

10-Q 2026-11-12 For: 2026-09-30
View Original
Added on November 13, 2026

About this 10-Q

Lineage Cell Therapeutics, Inc filed this 10-Q on November 12, 2026, covering the quarter ended September 30, 2026 (FY2026 Q3).

Lineage acquired NeuroAirmid on November 12, 2026, adding the HUNT1 cell therapy for Huntington’s Disease. It paid $2.4 million in cash and issued 2.2 million common shares, with up to $48.0 million contingent on clinical development and regulatory milestones. AI summary

Headline figures

Quarter ended September 30, 2026, as reported in this filing, compared with the same period a year earlier where the filing states it.

Revenue
$1.43M
down 61.0% from $3.68M a year earlier
Net income
$4.23M
compared with a net loss of $29.78M a year earlier
Diluted EPS
-$0.03
compared with -$0.13 a year earlier